1. Empirical therapy for serious Gram-positive infections: making the right choice 
J. Segreti 
Clinical Microbiology and Infection 
Volume 15, Pages 5-10 (December 2009)
DOI: /j x
Copyright © 2009 European Society of Clinical Infectious Diseases Terms and Conditions

2. FIG. 1
The impact of inadequate therapy on mortality rates in bloodstream infections, ventilator-associated pneumonia, nosocomial pneumonia and methicillin-resistant Staphylococcus aureus (MRSA) sterile site infections [5,7–10].
Clinical Microbiology and Infection  , 5-10DOI: ( /j x)
Copyright © 2009 European Society of Clinical Infectious Diseases Terms and Conditions

3. FIG. 2
The impact of inappropriate therapy on mortality rates in bloodstream infections [4,11]. As defined by relevant investigators: therapy was appropriate if it was started within 2 days of the first positive blood culture, if the infecting microorganism was subsequently found to be susceptible in vitro to the drug administered, and if the antimicrobial was given intravenously [4]; therapy was appropriate if the initial antimicrobials, which were administered within 24 h after the acquisition of a blood culture sample, included at least one antimicrobial that was active in vitro and when the dosage and route of administration were consistent with current medical standards [11].
Clinical Microbiology and Infection  , 5-10DOI: ( /j x)
Copyright © 2009 European Society of Clinical Infectious Diseases Terms and Conditions

4. FIG. 3
Infection-related mortality according to the type of empirical therapy (β-lactam or vancomycin) in intravenous drug users with methicillin-susceptible Staphylococcus aureus endocarditis [18].
Clinical Microbiology and Infection  , 5-10DOI: ( /j x)
Copyright © 2009 European Society of Clinical Infectious Diseases Terms and Conditions